Lonza builds in India in Simbiosys deal; updates on Patheon takeover

By Gareth Macdonald

- Last updated on GMT

Related tags: Dna, Lonza

Lonza says that to the Indian market was a key motivation for its acquisition of Simbiosys Biowares India preclinical cell and molecular biology assets.

On Tuesday, the Swiss healthcare services provider said it had bought the Bangalore-based unit, which employs 40 people and provides a variety of discovery, molecular biology and biopharmaceutical research services.

Company spokesman Dominik Werner told in-PharmaTechnologist that, in addition to building Lonza presence in India, Simbiosys’ expertise in cell-based clinical research and tissue sourcing had been critical factors in the move, explaining that both services are a good fit for Lonza LBS Cell Discovery unit.

Werner added that: “The preclinical cell and molecular biology group of Simbiosys Biowares India is aligned with Lonza’s strategy to continue to develop its life-science platform and to expand its global cell-biology portfolio.

The deal further strengthens Lonza’s position as a worldwide leader in cell discovery by integrating a unique service model into its portfolio and by continuing to develop the company’s activities​.”

Patheon exclusivity period extended

In a separate announcement released today, Lonza and the special committee of independent director set up by Canadian contract manufacturing organisation (CMO) Patheon have extended their exclusivity period for takeover discussions.

Lonza and Patheon say they are continuing to explore a possible takeover, which could see the contracting group integrated into the Swiss firm’s wider health care sector service offering.

The exclusivity period, which was due to expire today, will remain in place until terminated by either party.

Related topics: Mergers and Acquisitions

Related news

Show more